达格列净联合利拉鲁肽在2型糖尿病患者中的治疗效果及对糖脂代谢的影响研究

Study on the Therapeutic Effect of Dapagliflozin Combined with Liraglutide in Type 2 Diabetic Patients and the Effect on Glucolipid Metabolism

目的探讨达格列净联合利拉鲁肽在2型糖尿病患者中的治疗效果及对糖脂代谢的影响。方法选择2020年1月—2022年1月安丘市人民医院收治的100例接受治疗2型糖尿病患者为研究对象,采取随机数表法均等分组,每组50例,选择利拉鲁肽治疗为对照组,选择利拉鲁肽+达格列净治疗为观察组,对比不同治疗方案的疗效。结果观察组总有效率高于对照组,差异有统计学意义(P<0.05)。观察组TG、TC、LDL-C及HDL-C指标改善优于对照组,差异有统计学意义(P<0.05)。观察组FPG、2 hPG、HbA1c低于对照组。差异有统计学意义(P<0.05)。观察组APN、GSH-Px、SOD改善优于对照组。差异有统计学意义(P<0.05)。结论达格列净联合利拉鲁肽可提高临床疗效,改善患者血糖指标和糖脂代谢指标,提升APN和氧化应激。

Objective To investigate the therapeutic effect of dapagliflozin combined with liraglutide in patients with type 2 diabetes mellitus and its effect on glucolipid metabolism.Methods From January 2020 to January 2022,100 patients with type 2 diabetes treated in Anqiu People's Hospital were selected as the research objects.They were equally divided into groups by random number table method,50 cases in each group.Liraglutide was selected as the control group,Liraglutide+dapagliflozin was selected as the observation group to compare the efficacy of different treatment regimens.Results The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).The improvement of TG,TC,LDL-C and HDL-C in the observation group was better than that in the control group,and the difference was statistically significant(P<0.05).FPG,2 hPG and HbA1c in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).The improvement of APN,GSH-Px and SOD in the observation group was better than that in the control group,the difference was statistically significant(P<0.05).Conclusion Dapagliflozin combined with liraglutide can improve clinical efficacy,improve patients'glycemic index and glucolipid metabolic index,and enhance APN and oxidative stress.